MedTrace Logo

Effects of Coenzyme Q10 in Progressive Supranuclear Palsy (PSP)

NCT00382824 · Status: COMPLETED · Phase: NA · Type: INTERVENTIONAL · Enrollment: 61

Last updated 2019-08-01

Study results available
· View outcomes & findings →

Summary

The clinical syndrome of PSP responds poorly to all available forms of therapy used in Parkinson's Disease (PD). Currently, no effective treatment exists. Coenzyme Q10 in high doses has been shown to be a beneficial therapy in PD and might possibly be a beneficial therapy for PSP. This study will compare the efficacy, safety and tolerability of Coenzyme Q10 versus placebo in patients with atypical parkinsonian syndrome, progressive supranuclear palsy (PSP).

Conditions

Interventions

DIETARY_SUPPLEMENT

Coenzyme Q10

active drug

OTHER

Placebo

Placebo

Sponsors & Collaborators

  • Lahey Clinic

    lead OTHER

Principal Investigators

  • Diana Apetauerova, MD · Lahey Clinic

Study Design

Allocation
RANDOMIZED
Purpose
TREATMENT
Masking
QUADRUPLE
Model
PARALLEL

Eligibility

Min Age
30 Years
Sex
ALL
Healthy Volunteers
No

Timeline & Regulatory

Start
2006-09-30
Primary Completion
2013-09-30
Completion
2015-01-31

Countries

  • United States

Study Locations

More Related Trials

Entities

Diseases

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT00382824 on ClinicalTrials.gov